Stempoint Capital LP Purchases New Position in Alumis Inc. $ALMS

Stempoint Capital LP bought a new stake in shares of Alumis Inc. (NASDAQ:ALMS) during the 1st quarter, HoldingsChannel reports. The firm bought 229,566 shares of the company’s stock, valued at approximately $5,057,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC bought a new stake in shares of Alumis in the first quarter worth $46,790,000. Ally Bridge Group NY LLC bought a new position in Alumis during the first quarter worth $3,678,000. EverSource Wealth Advisors LLC lifted its stake in Alumis by 600.4% during the first quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock worth $69,000 after purchasing an additional 2,684 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Alumis by 2,222.5% in the first quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock worth $1,781,000 after purchasing an additional 77,364 shares during the period. Finally, Elmind Capital LP acquired a new position in Alumis in the first quarter worth $2,864,000.

Insider Buying and Selling at Alumis

In other news, insider Sanam Pangali sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $28.00, for a total transaction of $140,000.00. Following the sale, the insider owned 11,111 shares in the company, valued at $311,108. The trade was a 31.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 33.70% of the stock is currently owned by company insiders.

Alumis Trading Down 2.4%

Shares of ALMS opened at $26.38 on Thursday. The business’s 50-day moving average price is $24.82 and its 200 day moving average price is $25.03. The stock has a market capitalization of $3.36 billion, a P/E ratio of -13.32 and a beta of -0.73. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. On average, research analysts predict that Alumis Inc. will post -2.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Morgan Stanley restated an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Chardan Capital lifted their target price on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. Citigroup reiterated a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Finally, Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.